Dr. Gage arrives with a documented history of guiding compounds through FDA Investigational New Drug approvals. Her background encompasses small molecules, biologics, and cell therapies, specifically involving biomarker identification—a skillset Psilera intends to leverage for its upcoming safety and tolerability studies. She will work directly under Magali Haas, the company’s Chief Medical Officer, to navigate the transition from laboratory development to human clinical validation.

PSIL-006 is being developed as a next-generation treatment for neuropsychiatric conditions including PTSD, depression, and neurodegeneration. Engineered via the company’s Third Eye computational platform, the drug acts as a selective agonist at serotonin receptors. Unlike traditional psychedelic therapies, the molecule is designed to remove the need for clinic-based supervision or hallucinogenic effects, aiming instead for a scalable, take-home dosing model. This appointment follows a period of financial growth for the firm, which recently closed an $8.8 million seed round and secured NIH grant funding for its pre-clinical studies.